Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Surmodics, Inc. - Common Stock (NQ:SRDX)

27.99 -0.01 (-0.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Surmodics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Surmodics, Inc. (NASDAQ:SRDX) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 02/07/2023 -- An investigation was announced over potential securities laws violations by Surmodics, Inc. in connection with certain financial statements. 
Via SBWire
Surmodics Reports First Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
Surmodics to Report First Quarter of Fiscal 2023 Financial Results on February 6
From Surmodics, Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surmodics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Surmodics, Inc. (SRDX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SRDX EQUITY ALERT: Rosen Law Firm Encourages Surmodics Inc. Investors to Inquire About Securities Class Action Investigation – SRDX
From Rosen Law Firm
Via Business Wire
Differentiated Capabilities of Surmodics’ Crystalline Drug Release Platform for Sirolimus-Coated Balloons Presented at ISET Conference
From Surmodics, Inc.
Via Business Wire
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
From Surmodics, Inc.
Via Business Wire
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18
From Surmodics, Inc.
Via Business Wire
Surmodics Announces 12-Month Data from the SWING Trial Presented at VEITHsymposium
From Surmodics, Inc.
Via Business Wire
Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Fourth Quarter and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Financial Guidance
From Surmodics, Inc.
Via Business Wire
24-Month Data from Surmodics’ TRANSCEND Trial Presented at VIVA 2022 Conference
From Surmodics, Inc.
Via Business Wire
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
From Surmodics, Inc.
Via Business Wire
Surmodics Announces TRANSCEND Trial 24-Month Data to be Presented at VIVA 2022
From Surmodics, Inc.
Via Business Wire
Surmodics Announces New Credit Facilities Providing up to $125 Million in Financing
From Surmodics, Inc.
Via Business Wire
6-Month Data from the Surmodics SWING BTK First-in-Human Trial Presented at AMP Europe
From Surmodics, Inc.
Via Business Wire
6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe
From Surmodics, Inc.
Via Business Wire
Surmodics to Present at Upcoming Gilmartin Emerging Growth Company Showcase Wednesday, August 31, 2022
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Third Quarter Fiscal 2022 Results
From Surmodics, Inc.
Via Business Wire
Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27
From Surmodics, Inc.
Via Business Wire
Surmodics to Present at Jefferies Healthcare Conference
From Surmodics, Inc.
Via Business Wire
Surmodics Reports Second Quarter Fiscal 2022 Results
From Surmodics, Inc.
Via Business Wire
Pounce™ Thrombectomy System First-in-Human Data Show 100 Percent Technical Success in Early Cases
From Surmodics, Inc.
Via Business Wire
Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
From Surmodics, Inc.
Via Business Wire
Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27
From Surmodics, Inc.
Via Business Wire
Surmodics to Host Virtual Annual Meeting of Shareholders
From Surmodics, Inc.
Via Business Wire
Surmodics Reports First Quarter Fiscal 2022 Results
From Surmodics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.